Objectives: Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/r) provides an alternative treatment option for HIV-1 infection that spares nucleoside analogs (NRTI) for future use and decreased toxicity. We hypothesized that the level of immune activation (IA) and recovery of lymphocyte populations could influence virologic outcomes after regimen simplification. Methods: Thirty-four participants with virologic suppression $48 weeks on antiretroviral therapy (2 NRTI plus protease inhibitor) were switched to ATV/r alone in the context of the ACTG 5201 clinical trial. Flow cytometric analyses were performed on PBMC isolated from 25 patients with available samples, of which 24 had lymphocyte recovery sufficient for this study...
BACKGROUND:: Achieving virologic suppression is a clear therapeutic goal for patients receiving comb...
Objectives: AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of tr...
OBJECTIVE: When to start highly active antiretroviral therapy (HAART) in asymptomatic chronically HI...
Objectives: Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/r) provides an alt...
OBJECTIVES: Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/r) provides an alt...
Objectives:The objective of this study was to assess the 48-week virological efficacy of atazanavir/...
OBJECTIVES: To explore 48 week safety and efficacy of treatment simplification to atazanavir/ritonav...
Objectives: The AtLaS-M randomized trial showed that in patients with HIV-1 RNA <50 copies/mL on ata...
Switch to unboosted atazanavir (ATV) is an attractive option due to convenience and tolerability in ...
Objective: To compare regimens consisting of either ritonavir-boosted atazanavir or efavirenz and a ...
Introduction: Since antiretroviral therapy must be taken lifelong, persistence and safety have becom...
Objectives: Although outcomes of antiretroviral therapy (ART) have been evaluated in randomized cont...
BACKGROUND: In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infec...
Introduction: We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, op...
Objectives: Natural killer (NK) cell function was investigated in Malaysian HIV patients beginning a...
BACKGROUND:: Achieving virologic suppression is a clear therapeutic goal for patients receiving comb...
Objectives: AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of tr...
OBJECTIVE: When to start highly active antiretroviral therapy (HAART) in asymptomatic chronically HI...
Objectives: Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/r) provides an alt...
OBJECTIVES: Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/r) provides an alt...
Objectives:The objective of this study was to assess the 48-week virological efficacy of atazanavir/...
OBJECTIVES: To explore 48 week safety and efficacy of treatment simplification to atazanavir/ritonav...
Objectives: The AtLaS-M randomized trial showed that in patients with HIV-1 RNA <50 copies/mL on ata...
Switch to unboosted atazanavir (ATV) is an attractive option due to convenience and tolerability in ...
Objective: To compare regimens consisting of either ritonavir-boosted atazanavir or efavirenz and a ...
Introduction: Since antiretroviral therapy must be taken lifelong, persistence and safety have becom...
Objectives: Although outcomes of antiretroviral therapy (ART) have been evaluated in randomized cont...
BACKGROUND: In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infec...
Introduction: We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, op...
Objectives: Natural killer (NK) cell function was investigated in Malaysian HIV patients beginning a...
BACKGROUND:: Achieving virologic suppression is a clear therapeutic goal for patients receiving comb...
Objectives: AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of tr...
OBJECTIVE: When to start highly active antiretroviral therapy (HAART) in asymptomatic chronically HI...